A potent soluble epoxide hydrolase inhibitor, t-AUCB, modulates cholesterol balance and oxidized low density lipoprotein metabolism in adipocytes in vitro

Biological Chemistry

Volumn 395, Issue 4, 2014, Pages 443-451

  Shen, Li ^a   Peng, Hongchun ^b   Zhao, Shuiping ^a   Xu, Danyan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CHANGSHA CENTRAL HOSPITAL   (China)

Author keywords

adipocytokine; cholesterol efflux; epoxyeicosatrienoic acids; oxLDL; soluble epoxide hydrolase

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4 [4 [3 (1 ADAMANTYL)UREIDO]CYCLOHEXYLOXY]BENZOIC ACID; ABC TRANSPORTER A1; ADIPONECTIN; CD36 ANTIGEN; CHOLESTEROL; EPOXIDE HYDROLASE; IODINE 125; MESSENGER RNA; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA; 4-(4-(3-ADAMANTAN-1-YLUREIDO)CYCLOHEXYLOXY)BENZOIC ACID; BENZOIC ACID DERIVATIVE; ENZYME INHIBITOR; LOW DENSITY LIPOPROTEIN; UREA;

ADIPOCYTE; ARTICLE; CELL DIFFERENTIATION; CULTURE MEDIUM; CYTOKINE RELEASE; ENDOCYTOSIS; ENZYME INHIBITION; HOMEOSTASIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LIPID DEGRADATION; LIPOPROTEIN METABOLISM; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; 3T3 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; MOUSE; OXIDATION REDUCTION REACTION; SOLUBILITY; STRUCTURE ACTIVITY RELATION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BENZOATES; CELLS, CULTURED; CHOLESTEROL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; EPOXIDE HYDROLASES; LIPOPROTEINS, LDL; MICE; OXIDATION-REDUCTION; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84896753127     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/hsz-2013-0251     Document Type: Article

References (32)

1. Cawthorn, W.P. and Sethi, J.K. (2008). TNF-alpha and adipocyte biology. FEBS Lett. 582, 117-131.
2. Chui, P.C., Guan, H.P., Lehrke, M., and Lazar, M.A. (2005). PPARgamma regulates adipocyte cholesterol metabolism via oxidized LDL receptor 1. J. Clin. Invest. 115, 2244-2256. (Pubitemid 41134167)
3. De Taeye, B.M., Morisseau, C., Coyle, J., Covington, J.W., Luria, A., Yang, J., Murphy, S.B., Friedman, D.B., Hammock, B.B., and Vaughan, D.E. (2010). Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity (Silver Spring) 18, 489-498
4. do Carmo, J.M., da Silva, A.A., Morgan, J., Jim Wang, Y.X., Munusamy, S., and Hall, J.E. (2012). Inhibition of soluble epoxide hydrolase reduces food intake and increases metabolic rate in obese mice. Nutr. Metab. Cardiovasc. Dis. 22, 598-604.
5. Falcao-Pires, I., Castro-Chaves, P., Miranda-Silva, D., Lourenco, A.P., and Leite-Moreira, A.F. (2012). Physiological, pathological and potential therapeutic roles of adipokines. Drug Discov. Today 17, 880-889.
6. Fraley, A.E. and Tsimikas, S. (2006). Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr. Opin. Lipidol. 17, 502-509. (Pubitemid 44372680)
7. Han, J., Hajjar, D.P., Zhou, X., Gotto, A.M., Jr., and Nicholson, A.C. (2002). Regulation of peroxisome proliferator-activated receptor-gamma-mediated gene expression. A new mechanism of action for high density lipoprotein. J. Biol. Chem. 277, 23582-23586. (Pubitemid 34952194)
8. Hwang, S.H., Tsai, H.J., Liu, J.Y., Morisseau, C., and Hammock, B.D. (2007). Orally bioavailable potent soluble epoxide hydrolase inhibitors. J. Med. Chem. 50, 3825-3840. (Pubitemid 47292046)
9. Inceoglu, B., Wagner, K.M., Yang, J., Bettaieb, A., Schebb, N.H., Hwang, S.H., Morisseau, C., Haj, F.G., and Hammock, B.D. (2012). Acute augmentation of epoxygenated fatty acid levels rapidly reduces pain-related behavior in a rat model of type I diabetes. Proc. Natl. Acad. Sci. USA 109, 11390-11395.
10. Ishigaki, Y., Katagiri, H., Gao, J., Yamada, T., Imai, J., Uno, K., Hasegawa, Y., Kaneko, K., Ogihara, T., Ishihara, H., et al. (2008). Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118, 75-83.
11. Iyer, A., Kauter, K., Alam, M.A., Hwang, S.H., Morisseau, C., Hammock, B.D., and Brown, L. (2012). Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp. Diabetes Res. 2012, 758614.
12. Jin, X., Yi, L., Chen, M.L., Chen, C.Y., Chang, H., Zhang, T., Wang, L., Zhu, J.D., Zhang, Q.Y., and Mi, M.T. (2013). Delphinidin-3-glucoside protects against oxidized low-density lipoprotein-induced mitochondrial dysfunction in vascular endothelial cells via the sodium-dependent glucose transporter SGLT1. PLoS One 8, e68617.
13. Katagiri, H., Yamada, T., and Oka, Y. (2007). Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ. Res. 101, 27-39. (Pubitemid 47094621)
14. Kim, D.H., Vanella, L., Inoue, K., Burgess, A., Gotlinger, K., Manthati, V.L., Koduru, S.R., Zeldin, D.C., Falck, J.R., Schwartzman, M.L., et al. (2010). Epoxyeicosatrienoic acid agonist regulates human mesenchymal stem cell-derived adipocytes through activation of HO-1-pAKT signaling and a decrease in PPARgamma. Stem Cells Dev. 19, 1863-1873.
15. Kuniyasu, A., Hayashi, S., and Nakayama, H. (2002). Adipocytes recognize and degrade oxidized low density lipoprotein through CD36. Biochem. Biophys. Res. Commun. 295, 319-323. (Pubitemid 34785836)
16. Liu, Y., Dang, H., Li, D., Pang, W., Hammock, B. D., and Zhu, Y. (2012). Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice. PLoS One 7, e39165.
17. Liu, Y., Zhang, Y., Schmelzer, K., Lee, T.S., Fang, X., Zhu, Y., Spector, A.A., Gill, S., Morisseau, C., Hammock, B.D., et al. (2005). The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc. Natl. Acad. Sci. USA 102, 16747-16752. (Pubitemid 41688848)
18. Lorthioir, A., Guerrot, D., Joannides, R., and Bellien, J. (2012). Diabetic CVD-soluble epoxide hydrolase as a target. Cardiovasc. Hematol. Agents Med. Chem. 10, 212-222.
19. Morisseau, C. and Hammock, B.D. (2013). Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu. Rev. Pharmacol. Toxicol. 53, 37-58.
20. Pang, W., Li, N., Ai, D., Niu, X.L., Guan, Y.F., and Zhu, Y. (2011). Activation of peroxisome proliferator-activated receptor-gamma downregulates soluble epoxide hydrolase in cardiomyocytes. Clin. Exp. Pharmacol. Physiol. 38, 358-364.
21. Sodhi, K., Inoue, K., Gotlinger, K.H., Canestraro, M., Vanella, L., Kim, D.H., Manthati, V.L., Koduru, S.R., Falck, J.R., Schwartzman, M.L., et al. (2009). Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. J. Pharmacol. Exp. Ther. 331, 906-916.
22. van der Zwan, L.P., Teerlink, T., Dekker, J.M., Henry, R.M., Stehouwer, C.D., Jakobs, C., Heine, R.J., and Scheffer, P.G. (2009). Circulating oxidized LDL: determinants and association with brachial flow-mediated dilation. J. Lipid. Res. 50, 342-349.
23. Verghese, P.B., Arrese, E.L., and Soulages, J.L. (2007). Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes. Mol. Cell. Biochem. 302, 241-248. (Pubitemid 47202340)
24. Wang, Y.X., Ulu, A., Zhang, L.N., and Hammock, B. (2010). Soluble epoxide hydrolase in atherosclerosis. Curr. Atheroscler. Rep. 12, 174-183.
25. Wu, Z.H. and Zhao, S.P. (2009). Niacin promotes cholesterol efflux through stimulation of the PPARgamma-LXRalpha-ABCA1 pathway in 3T3-L1 adipocytes. Pharmacology 84, 282-287.
26. Xu, X., Zhang, X.A., and Wang, D.W. (2011). The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv. Drug Deliv. Rev. 63, 597-609.
27. Xu, X., Zhao, C.X., Wang, L., Tu, L., Fang, X., Zheng, C., Edin, M.L., Zeldin, D.C., and Wang, D.W. (2010). Increased CYP2J3 expression reduces insulin resistance in fructose-treated rats and db/db mice. Diabetes 59, 997-1005.
28. Yu, B.L., Zhao, S.P., and Hu, J.R. (2010). Cholesterol imbalance in adipocytes: a possible mechanism of adipocytes dysfunction in obesity. Obes. Rev. 11, 560-567.
29. Zhang, Y., McGillicuddy, F.C., Hinkle, C.C., O'Neill, S., Glick, J.M., Rothblat, G.H., and Reilly, M.P. (2010). Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 121, 1347-1355.
30. Zhang, L N., Vincelette, J., Cheng, Y., Mehra, U., Chen, D., Anandan, S.K., Gless, R., Webb, H.K., and Wang, Y.X. (2009). Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler. Thromb. Vasc. Biol. 29, 1265-1270.
31. Zhao, S.P. and Zhang, D.Q. (2004). Atorvastatin enhances cellular uptake of oxidized LDL in adipocytes from hypercholes-terolemic rabbits. Clin. Chim. Acta 339, 189-194.
32. Zhao, S.P., Wu, J., Zhang, D.Q., Ye, H.J., Liu, L., and Li, J.Q. (2004). Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit. Atherosclerosis 177, 255-262. (Pubitemid 39505255)